查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球語音生物標誌物市場:市場規模、份額、趨勢分析、機會、預測-按類型、適應症、神經系統疾病、最終用戶、地區 (2019-2029)
市場調查報告書
商品編碼
1227602

全球語音生物標誌物市場:市場規模、份額、趨勢分析、機會、預測-按類型、適應症、神經系統疾病、最終用戶、地區 (2019-2029)

Vocal Biomarkers Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type, By Indications, By Neurological Disorders, By End User, By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球語音生物標誌物市場規模將在 2022 年達到 30.1 億美元，到 2029 年達到 62.2 億美元，在 2023-2029 年的預測期內以 11% 的複合年增長率增長。

在帕金森病和其他疾病患病率上升、對診斷各種疾病的微創治療需求激增以及心血管和精神疾病發病率上升的推動下，全球市場正在蓬勃發展。

本報告考察了全球語音生物標誌物市場，並提供了市場洞察、市場概況、區域市場分析、競爭格局、公司概況等資訊。

目次

第 1 章研究框架

第 2 章執行摘要

第 3 章全球語音生物標誌物市場洞察

  • 工業價值鏈分析
  • DROC 分析
    • 促進因素
      • 帕金森病和其他疾病的患病率上升
      • 對用於診斷各種疾病的微創治療的需求激增
      • 心血管和精神疾病的發病率上升
    • 抑制因素
      • 語音生物標誌物的錯誤和不準確
      • 高技術成本
    • 機會
      • 增加語音生物標誌物研究調查
      • 語音生物標誌物的成功臨床試驗
    • 任務
  • 技術進步/最新發展
  • 監管框架
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭激烈程度

第 4 章全球語音生物標誌物市場概述

  • 2019-2029 年市場規模和預測
    • 按金額（十億美元）
  • 市場份額/預測
    • 按類型
      • 頻率
      • 振幅
      • 錯誤率
      • 音頻上升/下降時間
      • 工作時間
      • 聲音震顫
      • 推介
    • 根據指示
      • 抑鬱症
      • 注意力不集中
      • 破壞性行為障礙
      • 其他
    • 神經系統疾病
      • 帕金森病
      • 阿爾茨海默病
      • 亨廷頓舞蹈症
      • 呼吸和心血管疾病
      • 創傷性腦損傷
    • 最終用戶
      • 醫院和診所
      • 學術研究所
      • 其他
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

第 5 章北美語音生物標記市場

  • 2019-2029 年市場規模和預測
    • 按金額（十億美元）
  • 市場份額/預測
    • 按類型
    • 根據指示
    • 神經系統疾病
    • 最終用戶
    • 按國家
      • 美國
      • 加拿大

第 6 章歐洲之聲生物標誌物市場

  • 2019-2029 年市場規模和預測
    • 按金額（十億美元）
  • 市場份額/預測
    • 按類型
    • 根據指示
    • 神經系統疾病
    • 最終用戶
    • 按國家
      • 德國
      • 英國
      • 意大利
      • 法國
      • 西班牙
      • 荷蘭
      • 其他歐洲

第 7 章亞太語音生物標誌物市場

  • 2019-2029 年市場規模和預測
    • 按金額（十億美元）
  • 市場份額/預測
    • 按類型
    • 根據指示
    • 神經系統疾病
    • 最終用戶
    • 按國家
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳大利亞和新西蘭
      • 印度尼西亞
      • 馬來西亞
      • 新加坡
      • 菲律賓
      • 越南
      • 亞太其他地區

第 8 章拉丁美洲語音生物標誌物市場

  • 2019-2029 年市場規模和預測
    • 按金額（十億美元）
  • 市場份額/預測
    • 按類型
    • 根據指示
    • 神經系統疾病
    • 最終用戶
    • 按國家
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 哥倫比亞
      • 其他拉丁美洲

第 9 章中東和非洲語音生物標誌物市場

  • 2019-2029 年市場規模和預測
    • 按金額（十億美元）
  • 市場份額/預測
    • 按類型
    • 根據指示
    • 神經系統疾病
    • 最終用戶
    • 按國家
      • 沙特阿拉伯
      • 阿拉伯聯合酋長國
      • 卡塔爾
      • 科威特
      • 南非
      • 尼日利亞
      • 阿爾及利亞
      • 其他中東和非洲地區

第 10 章競爭格局

  • 主要公司和產品列表
  • 2022 年全球語音生物標誌物公司的市場份額分析
  • 競爭基準：按運營參數
  • 重大戰略發展（合併、收購、合作等）

第 11 章 COVID-19 對全球語音生物標誌物市場的影響

第 12 章公司概況（公司概況、財務矩陣、競爭格局、主要人員、主要競爭對手、聯繫地址、戰略前景、SWOT分析）

  • Sonde Health
  • Beyond Verbal
  • IBM Corporation
  • Cogito Corporation
  • Boston Technology Corporation
  • Microtest Health
  • 其他有影響力的公司

第 13 章關鍵戰略建議

第 14 章研究方法論

簡介目錄
Product Code: BWC20123

Global Vocal Biomarker Market Size More Than Doubles Cross USD 6.2 Billion by 2029.

Global vocal biomarker market is flourishing because of rising prevalence of Parkinson's and other diseases, a surging demand for minimally invasive treatments to diagnose different illnesses, and the increasing incidence of cardiovascular and mental disorders.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global vocal biomarker market size at USD 3.01 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global vocal biomarker market size to grow at a significant CAGR of 11% reaching a value of USD 6.22 billion by 2029. Major growth drivers for global vocal biomarker market include increasing incidence of neurological, psychological, and other speech-related diseases, including attention deficit, Parkinson's disease, depression, and cardiovascular diseases. These disorders necessitate less invasive tests for treatment, resulting in an increase in demand for vocal biomarkers. Vocal biomarkers are mainly used to detect illnesses using non-invasive speech features. Its use is based on the premise that severe illnesses have an effect on motor control and so change speech output by changing speech features. Vocal biomarkers are increasingly being employed to detect neurological disorders. Alzheimer's, schizophrenia, and Parkinson's disease typically manifest at a later stage of the disease, limiting the doctor's capacity to implement harsh measures. This allows pharmaceutical companies to create and test vocal biomarkers to aid in the early detection of such illnesses. Aside from healthcare, voice biomarkers have uses in lie detection. They are thought to be useful in defense and security organizations while questioning a criminal. Therefore, such factors are expected to fuel the expansion of overall market during period in analysis. However, errors and inaccuracy of vocal biomarkers is expected to hinder market growth.

Global Vocal Biomarker Market - Overview:

In the event of serious illnesses, early disease identification might mean the difference between a person's life and death. The development of new techniques that assist physicians and patients in diagnosing illnesses early has decreased death rates. Vocal biomarkers are one such advancement in the world of medicine. A human body's symptom or medical condition can be a biomarker. It is the pattern of speech in the case of vocal biomarkers. The vocal biomarkers market growth has been expanding steadily over the past several years and is predicted to have an extraordinary development in the years to come. Vocal biomarkers offer several benefits that increase their market demand. The requirement for early illness diagnosis, particularly from developed and developing nations, is one of the most crucial elements. Additionally, it is now among the most economical methods for illness diagnosis.

Global Vocal Biomarker Market - By Type:

By type, the global vocal biomarker market is segmented into amplitude, error rate, frequency, vocal rise or fall duration, voice tremor, pitch, and phonation time. The voice tremor segment is expected to hold the highest market share. It is a neurological condition that results in the uncontrollable movement of the vocal cords and throat muscles. The market dynamics will also be further influenced by the rising prevalence of neurological illnesses and the developing use of vocal tremors in neurological disorders.

Impact of COVID-19 on Global Vocal Biomarkers Market

The COVID-19 had a detrimental impact on the voice biomarkers industry globally. The pandemic has hampered the production and supply of voice biomarkers worldwide for various illnesses in these major economies. However, COVID-19 therapy now includes employs voice biomarkers. For instance, in December 2021, Vocalis Health developed a software program called Vocalis Check that evaluates a person's voice if they have an uncertain COVID-19 status. Due to the current worldwide pandemic, these developments are expected to significantly accelerate market growth and present possibilities for industry participants. The pandemic has led to an increase in the use of telemedicine and remote monitoring technologies, and vocal biomarkers may be able to play a role in these systems. For example, vocal biomarkers could potentially be used to assess the health status of patients remotely and to provide information to healthcare providers about changes in a patient's condition.

Competitive Landscape:

Major players operating in global vocal biomarker market include: Sonde Health, Beyond Verbal, IBM Corporation, Cogito Corporation, Boston Technology Corporation, and Microtest Health. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Vocal Biomarker Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Vocal Biomarker Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Vocal Biomarker Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Prevalence of Parkinson's Disease and Other Diseases
      • 3.2.1.2. Increasing Need for Minimally Invasive Treatments to Diagnose Different Illnesses
      • 3.2.1.3. Rising Incidence of Cardiovascular and Mental Disorders
    • 3.2.2. Restraints
      • 3.2.2.1. Errors and Inaccuracy of Vocal Biomarkers
      • 3.2.2.2. High Cost of Techniques
    • 3.2.3. Opportunities
      • 3.2.3.1. Increasing The Research Study of Vocal Biomarkers
      • 3.2.3.2. Successful Completion of Clinical Investigations of Voice Biomarker
    • 3.2.4. Challenges
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Vocal Biomarker Market Overview

  • 4.1. Market Size & Forecast by Value, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Frequency
      • 4.2.1.2. Amplitude
      • 4.2.1.3. Error Rate
      • 4.2.1.4. Vocal Rise or Fall Time
      • 4.2.1.5. Phonation Time
      • 4.2.1.6. Voice Tremor
      • 4.2.1.7. Pitch
    • 4.2.2. By Indication
      • 4.2.2.1. Depression
      • 4.2.2.2. Attention Deficit
      • 4.2.2.3. Disruptive Behavior Disorders
      • 4.2.2.4. Others
    • 4.2.3. By Neurological Disorders
      • 4.2.3.1. Parkinson's Disease
      • 4.2.3.2. Alzheimer's Disease
      • 4.2.3.3. Huntington's Disease
      • 4.2.3.4. Respiratory and Cardiovascular Disorders
      • 4.2.3.5. Traumatic Brain Injury
    • 4.2.4. By End User
      • 4.2.4.1. Hospitals and Clinics
      • 4.2.4.2. Academic and Research
      • 4.2.4.3. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific
      • 4.2.5.4. Latin America
      • 4.2.5.5. Middle East and Africa

5. North America Vocal Biomarker Market

  • 5.1. Market Size & Forecast by Value, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Indication
    • 5.2.3. By Neurological Disorders
    • 5.2.4. By End User
    • 5.2.5. By Country
      • 5.2.5.1. US
      • 5.2.5.1.1. By Type
      • 5.2.5.1.2. By Indication
      • 5.2.5.1.3. By Neurological Disorders
      • 5.2.5.1.4. By End User
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Type
      • 5.2.5.2.2. By Indication
      • 5.2.5.2.3. By Neurological Disorders
      • 5.2.5.2.4. By End User

6. Europe Vocal Biomarker Market

  • 6.1. Market Size & Forecast by Value, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Indication
    • 6.2.3. By Neurological Disorders
    • 6.2.4. By End User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Type
      • 6.2.5.1.2. By Indication
      • 6.2.5.1.3. By Neurological Disorders
      • 6.2.5.1.4. By End User
      • 6.2.5.2. UK
      • 6.2.5.2.1. By Type
      • 6.2.5.2.2. By Indication
      • 6.2.5.2.3. By Neurological Disorders
      • 6.2.5.2.4. By End User
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Type
      • 6.2.5.3.2. By Indication
      • 6.2.5.3.3. By Neurological Disorders
      • 6.2.5.3.4. By End User
      • 6.2.5.4. France
      • 6.2.5.4.1. By Type
      • 6.2.5.4.2. By Indication
      • 6.2.5.4.3. By Neurological Disorders
      • 6.2.5.4.4. By End User
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Type
      • 6.2.5.5.2. By Indication
      • 6.2.5.5.3. By Neurological Disorders
      • 6.2.5.5.4. By End User
      • 6.2.5.6. The Netherlands
      • 6.2.5.6.1. By Type
      • 6.2.5.6.2. By Indication
      • 6.2.5.6.3. By Neurological Disorders
      • 6.2.5.6.4. By End User
      • 6.2.5.7. Rest of Europe
      • 6.2.5.7.1. By Type
      • 6.2.5.7.2. By Indication
      • 6.2.5.7.3. By Neurological Disorders
      • 6.2.5.7.4. By End User

7. Asia-Pacific Vocal Biomarker Market

  • 7.1. Market Size & Forecast by Value, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Indication
    • 7.2.3. By Neurological Disorders
    • 7.2.4. By End User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Type
      • 7.2.5.1.2. By Indication
      • 7.2.5.1.3. By Neurological Disorders
      • 7.2.5.1.4. By End User
      • 7.2.5.2. India
      • 7.2.5.2.1. By Type
      • 7.2.5.2.2. By Indication
      • 7.2.5.2.3. By Neurological Disorders
      • 7.2.5.2.4. By End User
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Type
      • 7.2.5.3.2. By Indication
      • 7.2.5.3.3. By Neurological Disorders
      • 7.2.5.3.4. By End User
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Type
      • 7.2.5.4.2. By Indication
      • 7.2.5.4.3. By Neurological Disorders
      • 7.2.5.4.4. By End User
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Type
      • 7.2.5.5.2. By Indication
      • 7.2.5.5.3. By Neurological Disorders
      • 7.2.5.5.4. By End User
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Type
      • 7.2.5.6.2. By Indication
      • 7.2.5.6.3. By Neurological Disorders
      • 7.2.5.6.4. By End User
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Type
      • 7.2.5.7.2. By Indication
      • 7.2.5.7.3. By Neurological Disorders
      • 7.2.5.7.4. By End User
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Type
      • 7.2.5.8.2. By Indication
      • 7.2.5.8.3. By Neurological Disorders
      • 7.2.5.8.4. By End User
      • 7.2.5.9. Philippines
      • 7.2.5.9.1. By Type
      • 7.2.5.9.2. By Indication
      • 7.2.5.9.3. By Neurological Disorders
      • 7.2.5.9.4. By End User
      • 7.2.5.10. Vietnam
      • 7.2.5.10.1. By Type
      • 7.2.5.10.2. By Indication
      • 7.2.5.10.3. By Neurological Disorders
      • 7.2.5.10.4. By End User
      • 7.2.5.11. Rest of Asia Pacific
      • 7.2.5.11.1. By Type
      • 7.2.5.11.2. By Indication
      • 7.2.5.11.3. By Neurological Disorders
      • 7.2.5.11.4. By End User

8. Latin America Vocal Biomarker Market

  • 8.1. Market Size & Forecast by Value, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Indication
    • 8.2.3. By Neurological Disorders
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Type
      • 8.2.5.1.2. By Indication
      • 8.2.5.1.3. By Neurological Disorders
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Type
      • 8.2.5.2.2. By Indication
      • 8.2.5.2.3. By Neurological Disorders
      • 8.2.5.2.4. By End User
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Type
      • 8.2.5.3.2. By Indication
      • 8.2.5.3.3. By Neurological Disorders
      • 8.2.5.3.4. By End User
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Type
      • 8.2.5.4.2. By Indication
      • 8.2.5.4.3. By Neurological Disorders
      • 8.2.5.4.4. By End User
      • 8.2.5.5. Colombia
      • 8.2.5.5.1. By Type
      • 8.2.5.5.2. By Indication
      • 8.2.5.5.3. By Neurological Disorders
      • 8.2.5.5.4. By End User
      • 8.2.5.6. Rest of LATAM
      • 8.2.5.6.1. By Type
      • 8.2.5.6.2. By Indication
      • 8.2.5.6.3. By Neurological Disorders
      • 8.2.5.6.4. By End User

9. Middle East & Africa Vocal Biomarker Market

  • 9.1. Market Size & Forecast by Value, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Indication
    • 9.2.3. By Neurological Disorders
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Type
      • 9.2.5.1.2. By Indication
      • 9.2.5.1.3. By Neurological Disorders
      • 9.2.5.1.4. By End User
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Type
      • 9.2.5.2.2. By Indication
      • 9.2.5.2.3. By Neurological Disorders
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Type
      • 9.2.5.3.2. By Indication
      • 9.2.5.3.3. By Neurological Disorders
      • 9.2.5.3.4. By End User
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Type
      • 9.2.5.4.2. By Indication
      • 9.2.5.4.3. By Neurological Disorders
      • 9.2.5.4.4. By End User
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Type
      • 9.2.5.5.2. By Indication
      • 9.2.5.5.3. By Neurological Disorders
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Type
      • 9.2.5.6.2. By Indication
      • 9.2.5.6.3. By Neurological Disorders
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Type
      • 9.2.5.7.2. By Indication
      • 9.2.5.7.3. By Neurological Disorders
      • 9.2.5.7.4. By End User
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Type
      • 9.2.5.8.2. By Indication
      • 9.2.5.8.3. By Neurological Disorders
      • 9.2.5.8.4. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Vocal Biomarker Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, and others)

11. Impact of Covid-19 on Global Vocal Biomarker Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 12.1. Sonde Health
  • 12.2. Beyond Verbal
  • 12.3. IBM Corporation
  • 12.4. Cogito Corporation
  • 12.5. Boston Technology Corporation
  • 12.6. Microtest Health
  • 12.7. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations